Slide 1: Stock exchange cover letter: Investor Presentation Q4 & FY26
Date: 27/05/2026 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation – Q4 & FY26 Dear Sir/ Madam, Pleas
Slide 2: Q4 & FY26 Investor Presentation
Global Reach. Trusted Partner. Sustainable Impact. MOREPEN L Building Today. Transforming Tomorrow. Advancing Health. Expanding Possibilities. Q4 & FY26 Investor Presentation Driving Sustainable Growth Through CDMO Excellence and Long-Term Partnerships Scaling Manufacturing Long-Term Global Standard
Slide 3: Scaling Manufacturing Partnerships
Scaling Manufacturing Partnerships Beyond Generic APIs Foundation Strengths Strategic CDMO Expansion Strong Manufacturing Foundation Commercial Program Milestones Achieved 40+ years of API manufacturing execution Secured multi-year mandate (Rs. 823cr) Export presence across 90+ countries Commercial
Slide 4: Operating Leverage Ahead
Operating Leverage Ahead Utilisation. Scale. Margins. Manufacturing Capacity Expansion Operating Leverage Potential Long-term KL Exisitng 10-11% EBITDA Range Mid-term ~1000 KL Key Structural Drivers Long-term ~800 KL plan ✔ Long-duration Long-duration supply programs Exisitng Capacity Expansion ✔ Im
Slide 5: Quarterly & FY26 Highlights
Quarterly & FY26 Highlights Strong Finish to FY26 “FY26 marked an important transition year as 22% 17% 31% Morepen strengthened long-duration manufacturing partnerships, expanded capacities, and progressed Total API Devices toward a more scalable operating model.” Q4- Revenue Growth Revenue Momentum
Slide 6: Global Manufacturing Base
Global Manufacturing Base Global Scale. Proven Compliance. API Business Revenue Finished Breakup 88% Dosages Established API Manufacturing Platform Strategic Direction Four decades of manufacturing capability and customer trust Increasing focus on long-term supply contracts Established leadership po
Slide 7: Global Manufacturing Credibility
Global Manufacturing Credibility Strengthening Global Partnerships Manufacturing & Execution Strengths Global & Regulatory Footprint Large-scale API manufacturing infrastructure Export Presence Across 90+ Countries Multi-product API capabilities USFDA-Approved Manufacturing Facilities Proven global
Slide 8: Better Earnings Profile
Better Earnings Profile Better Mix. Better Margins. EBITDA Profile Evolution Business Evolution Historical Characteristics EBITDA Profile Evolution Transaction-led Transaction-led API sales EBITDA profile moving from Cyclical pricing environment ~11% to 20%+ 20%+ Evolving Characteristics Value Drive
Slide 9: Focused Growth Platforms
Focused Growth Platforms Two Distinct Growth Engines Pharma/API & CDMO Platform Medical Devices Platform Manufacturing-led growth platform (B2B) Consumer diagnostics platform Long-duration Long-duration regulated-market supply programs Home diagnostics and chronic care ecosystem Capacity expansion a
Slide 10: Devices at Scale
Devices at Scale One of India’s fast-growing consumer diagnostics device businesses Business Snapshot Strategic Focus Areas Rs. 597 Cr FY26 Revenue Blood Glucose Monitoring ~20% Annual Growth Blood Pressure Monitoring Installed base of ~17 Mn users Continuous Glucose Monitoring (CGM) Connected Healt
Slide 11: The Next Growth Phase
The Next Growth Phase Consumer Health Tailwinds Medical Devices Growth Platform Consumer Diagnostics & Chronic Care Expansion Distribution Expansion Focused Scaling Opportunitie Preventive Care Diabetes management Home diagnostics adoption Tier 2 / Tier 3 penetration Focused platform structure BP mo
Slide 12: Quarterly Momentum
Quarterly Momentum Continued Operational and Commercial Momentum (Rs. in crores) Gross Revenue EBITDA PAT 500 472 35 33 32 25 Operational Highlights 385 30 20 400 22% 20 Revenue growth supported supported by export momentum 4% 25 69% and Devices expansion 300 20 15 8.6% 12 4.3% Manufacturing scale-u
Slide 13: Annual Financial Momentum – FY26 (Standalone)
Annual Financial Momentum – FY26 (Standalone) Transition Year for Growth (Rs. in crores) Gross Revenue EBITDA PAT 2000 200 120 Key Business Dynamics During FY26 1703 169 102 API pricing environment remained volatile across select 1570 100 1500 150 135 categories during FY26 8% 80 66 Devices business
Slide 14: Safe Harbour
Safe Harbour This presentation has been prepared by Morepen Laboratories Limited (“Morepen” or the “Company”) for informational purposes only and does not constitute an offer, invitation, recommendation, or solicitation to purchase or subscribe to any securities. Certain statements contained in this
Slide 15: Thankyou
erg integrated pharma complex at baddi (HP) INDIA Thankyou www.morepen.com